Canaccord Genuity Maintains Buy on Boston Scientific, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a 'Buy' rating on Boston Scientific (NYSE:BSX) and raises the price target from $62 to $64.
September 21, 2023 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on Boston Scientific and raises the price target from $62 to $64.
The raised price target by Canaccord Genuity indicates a positive outlook for Boston Scientific. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100